- Home
- ULY vs APVO Comparison
ULY vs APVO Comparison
Compare ULY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- APVO
- Stock Information
- Founded
- ULY 2013
- APVO 2016
- Country
- ULY United States
- APVO United States
- Employees
- ULY N/A
- APVO N/A
- Industry
- ULY
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ULY
- APVO Health Care
- Exchange
- ULY Nasdaq
- APVO Nasdaq
- Market Cap
- ULY 5.8M
- APVO 21.7M
- IPO Year
- ULY N/A
- APVO N/A
- Fundamental
- Price
- ULY $2.28
- APVO $1.35
- Analyst Decision
- ULY Strong Buy
- APVO
- Analyst Count
- ULY 2
- APVO 0
- Target Price
- ULY $11.50
- APVO N/A
- AVG Volume (30 Days)
- ULY 36.0K
- APVO 815.9K
- Earning Date
- ULY 11-12-2025
- APVO 11-06-2025
- Dividend Yield
- ULY N/A
- APVO N/A
- EPS Growth
- ULY N/A
- APVO N/A
- EPS
- ULY N/A
- APVO N/A
- Revenue
- ULY $127,932,000.00
- APVO N/A
- Revenue This Year
- ULY N/A
- APVO N/A
- Revenue Next Year
- ULY $20.23
- APVO N/A
- P/E Ratio
- ULY N/A
- APVO N/A
- Revenue Growth
- ULY N/A
- APVO N/A
- 52 Week Low
- ULY $2.23
- APVO $1.32
- 52 Week High
- ULY $17.99
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- ULY 31.63
- APVO 40.05
- Support Level
- ULY $2.23
- APVO $1.39
- Resistance Level
- ULY $2.74
- APVO $1.54
- Average True Range (ATR)
- ULY 0.18
- APVO 0.09
- MACD
- ULY 0.00
- APVO -0.00
- Stochastic Oscillator
- ULY 7.46
- APVO 6.52
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.